Talecris Biotherapeutics (TLCR) Files $1 Billion IPO
More News related to TLCR
- Barclays Initiates Coverage on Talecris Biotherapeutics (TLCR) with an Equalweight
- Notable Analyst Rating Changes 11/10: ADBE, ANN, FRPT, RAX Upgraded; ALU, CPST, PIKE, TRW Downgraded
- Morning Movers 11/10: UPG, CYD, PCLN, FLL, BZH Higher; RHIE, OPXT, PRKR, PIKE, MBI, SDTH Lower
- Several Brokerage Firms Initiate Coverage on Talecris Biotherapeutics (TLCR)
- Goldman Sachs Starts Talecris Biotherapeutics (TLCR) at Neutral
More News related to IPOs
- GM's Chairman Says Focus Is On Paying Back Government, Not an IPO - WSJ
- Golden Green (CHOP) Announces 4.8M Common Offering at $5/Share
Talecris Biotherapeutics Holdings (Nasdaq: TLCR) has filed a registration statement with the SEC for an initial public offering of its common stock. The Company intends to apply to list its common units on the Nasdaq under the symbol “TLCR.” The proposed maximum aggregate offering price is $1 billion.
The offering is being made through Morgan Stanley, Goldman, Sachs & Co. and JPMorgan.
Talecris Biotherapeutics is a biopharmaceutical company that is one of the largest producers and marketers of plasma-derived protein therapies in the world. Talecris develops, produces, markets and distributes therapies that extend and enhance the lives of people suffering from chronic and acute, often life-threatening, conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns.
Related Categories
IPOsStocks Mentioned
+0.48Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
